A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole

References

• DaviesLMDrummondMFThe economic burden of schizophreniaPsychiatr Bull199014522555
   Google Scholar
• MurrayCJLopezADEvidence-based health policy: lessons from the Global Burden of Disease StudyScience19962747407438966556
   PubMed Web of Science ®Google Scholar
• BunneyWEMeltzerHYSchizophrenia: overviewClin Neurosci199535556
   Google Scholar
• KeckPEJrMcElroySLArnoldLMBipolar disorderMed Clin North Am20018564566111349478
   PubMed Web of Science ®Google Scholar
• AngstJThe emerging epidemiology of hypomania and bipolar II disorderJ Affect Disord1998501431519858074
   PubMed Web of Science ®Google Scholar
• Prevalence and incidence of bipolar disorder [homepage on the Internet]. Available from: www.wrongdiagnosis.com/b/bipolar/prevalence.htm Accessed September 11, 2008.
   Google Scholar
• GentileSExtrapyramidal adverse events associated with atypical anti-psychotic treatment of bipolar disorderJ Clinical Psychopharmacol200727354517224710
   PubMed Web of Science ®Google Scholar
• MeltzerHYThe role of serotonin in antipsychotic drug actionNeuropsychopharmacology1992212 supplS106S115
   Google Scholar
• KapurSSeemanPAntipsychotic agents differ in how fast they come off the dopamine D2 receptors: implication for atypical antipsychotic actionJ Psychiatry Neurosci20002516116610740989
   PubMed Web of Science ®Google Scholar
• KapurSSeemanPDoes fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?Am J Psychiatry200115836036911229973
   PubMed Web of Science ®Google Scholar
• SeemanPTallericoTAntipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptorsMol Psychiatry199831231349577836
   PubMed Web of Science ®Google Scholar
• GentileSAtypical antipsychotic for the treatment of bipolar disorder. More shadows than lightsCNS Drugs20072136738717447826
   PubMed Web of Science ®Google Scholar
• GentileSLong term atypical antipsychotics treatment and risk of weight gain. A literature analysisDrug Saf20062930331916569080
   PubMed Web of Science ®Google Scholar
• AichhornWWhitworthABWeissEMMarksteinerJSecond-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?Drug Saf200629758759816808551
   PubMed Web of Science ®Google Scholar
• FleishhackerWWMeiseUGuntherVKurzMCompliance with antipsychotic drug treatment: influence of side effectsActa Psychiatr Scand1994382supplS11S15
   Google Scholar
• GentileSAntipsychotic-associated weight gainAnn Pharmacother20043890390414996995
   PubMed Web of Science ®Google Scholar
• JordanSKoprivicaVChenRTottoriKKikuchiTAltarAThe antipsychotic aripiprazole is a potent, partial agonist at human 5-HT1A receptorEur J Pharmacol200244113714012063084
   PubMed Web of Science ®Google Scholar
• ReynoldsGPAntipsychotic drug mechanisms and neurotransmitter systems in schizophreniaActa Psychiatr Scand1994380suppl3640
   Web of Science ®Google Scholar
• ArgoTRCarnahanRMPerryPJAripiprazole, a novel antipsychotic drugPharmacotherapy20042421222814998222
   PubMed Web of Science ®Google Scholar
• BrixnerDISaidQCorey-lislePKNaturalistic impact of second-generation antipsychotics on weight gainAnn Pharmacother20064062663216569802
   PubMed Web of Science ®Google Scholar
• RaddymasuSBahtaELevinSManasKSlayLEElevated lipase and diabetic ketoacidosis associated with aripiprazoleJ Pancreas20067303305
   Google Scholar
• AllisonDBMackellJAMcDonnellDDThe impact of weight gain on quality of life among persons with schizophreniaPsychiatr Serv20035456556712663847
   PubMed Web of Science ®Google Scholar
• JonesPBBarnesTREDaviesLRandomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1)Arch Gen Psychiatry2006631079108717015810
   PubMed Web of Science ®Google Scholar
• NemeroffCBSafety of available agents used to treat bipolar disorder: focus on weight gainJ Clin Psychiatry20036453253912755655
   PubMed Web of Science ®Google Scholar
• WeidenPJMackellJAMcDonnellDDObesity as risk factor for antipsychotic noncomplianceSchizophr Res200466515714693352
   PubMed Web of Science ®Google Scholar
• NewcomerJWSecond-generation (atypical) antipsychotics and metabolic effects. A Comprehensive literature reviewCNS Drugs200519suppl 119315998156
   PubMed Web of Science ®Google Scholar
• HaddadPWeight change with atypical antipsychotics in the treatment of schizophreniaJ Psychopharmacol.200519suppl162716280334
   PubMedGoogle Scholar
• Álvarez-JiménezMGonzáles-BlanchCCrespo-FacorroBAntipsychotic-induced weight gain in chronic and first-episode psychotic disorders. A systematic critical reappraisalCNS Drugs20082254756218547125
   PubMed Web of Science ®Google Scholar
• PotkinSGSahaARKujawaMJAripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorderArch Gen Psychiatry20036068169012860772
   PubMed Web of Science ®Google Scholar
• ChanHYLinWWLinSKEfficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trialJ Clin Psychiatry200768293617284127
   PubMed Web of Science ®Google Scholar
• KaneJMCarsonWHSahaAREfficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorderJ Clin Psychiatry20076376377112363115
   PubMed Web of Science ®Google Scholar
• KaneJMMeltzerHYCarsonWHfor the aripiprazole Study GroupAripiprazole for treatment-resistant schizophrenia: results of a multi-center, randomized, double-blind, comparison versus perphenazineJ Clin Psychiatry20076821322317335319
   PubMed Web of Science ®Google Scholar
• KervinRMilletBHermanEA multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) studyEur Psychiatry20072243344317555947
   PubMed Web of Science ®Google Scholar
• KolotkinRLCorey-LisleyPKCrosbyRDKanHJMcQuadeRDChanges in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of careEur Psychiatry2008[Epub ahead of print].
   Web of Science ®Google Scholar
• McQuadeRDStockEMarcusRA comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomised, double-blind trialJ Clin Psychiatry200465suppl 18475615600384
   PubMed Web of Science ®Google Scholar
• NewcomerJWCamposJAMarcusRNA multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapineJ Clin Psychiatry2008691046105618605811
   PubMed Web of Science ®Google Scholar
• KimSHIvanovaOAbbasiFALambendolaCAReavenGMGlickIDMetabolic impact of switching antipsychotic therapy to aripiprazole after weight gainJ Clin Psychopharmacol20072736536817632220
   PubMed Web of Science ®Google Scholar
• SchorrSGSlooffCJPostemaRA 12-month follow-up study of treating overweight schizophrenic patients with aripiprazoleActa Psychiatr Scand200811824625018699955
   PubMed Web of Science ®Google Scholar
• CaseyDECarsonWHSahaARLiebeskindAAliMWJodyDSwitching patients to aripiprazole from another antipsychotic agent: a multicenter randomized studyPsychopharmacology200316639139912610718
   PubMed Web of Science ®Google Scholar
• KasperSLermanMNMcQuadeRDEfficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophreniaInt J Neuropsychopharmacol2003632533714609439
   PubMed Web of Science ®Google Scholar
• ChrzanowskiWKMarcusRNTorbeynsANyilasMEffectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapinePsychopharmacology200618925926617058105
   PubMed Web of Science ®Google Scholar
• McElroySSuppesTFryeMAOpen-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trialJ Affect Disord200710127528117229469
   PubMed Web of Science ®Google Scholar
• KeckPECalabreseJRMcQuadeRDA randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorderJ Clin Psychiatry20066762663716669728
   PubMed Web of Science ®Google Scholar
• KeckPECalabreseJRMcIntyreRSAripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placeboJ Clin Psychiatry2007681480149117960961
   PubMed Web of Science ®Google Scholar
• KeckPEJrMarcusRTourkodimitrisSAliMLiebeskindASahaAIngenitoGAripiprazole Study GroupA placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar maniaAm J Psychiatry200316091651165812944341
   PubMed Web of Science ®Google Scholar
• MarcusRNMcQuadeRDCarsonWHThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder. A second multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol20082815616518344725
   PubMed Web of Science ®Google Scholar
• BermanRMMarcusRNSwaninkRThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry20076884385317592907
   PubMed Web of Science ®Google Scholar
• HeinrichsDWHanlonTECarpenterWTJrThe Quality of Life Scale: an instrument for rating the schizophrenic deficit syndromeSchizophr Bull1984103883986474101
   PubMed Web of Science ®Google Scholar
• TaylorDHanssensLLozeJYPansML’ItalienGMarcusRNPreference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care. Results from the STAR studyEur Psychiatry20082333634318423987
   PubMed Web of Science ®Google Scholar
• EuroQol GroupEuroQol-a new facility for the measurement of health-related quality of lifeHealth Policy19901619920810109801
   PubMed Web of Science ®Google Scholar
• MitsonisCIDimopoulosNPMitropoulosPAKararizouEGKatsaANTsakirisFEAripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot studyProg Neuropsychopharm Biol Psychiatry200731373377
   Web of Science ®Google Scholar
• AwadAGVorugantiLNPImpact of atypical antipsychotics on quality of life in patients with schizophreniaCNS Drugs20041887789315521791
   PubMed Web of Science ®Google Scholar
• Quality of life compendiumCenter for Quality of Life Research in Nursing Science Section for Nursing Science, Department of Public Health and Primary Health Care, University of Bergen .[homepage on the Internet]. Available from URL: http://www.uib.no/isf/people/doc/qol/httoc.htm Accessed: 14 November 2008.
   Google Scholar
• El-SayehHGMorgantiCAripiprazole for schizophrenia (review)Cochrane Database Syst Rev.20042CD004578.pub215106256
   PubMedGoogle Scholar
• WirshingDWirshingAAripiprazole. A viewpointCNS Drugs200216787788
   Web of Science ®Google Scholar
• McGavinJKGoaKLAripiprazoleCNS Drugs20021677978612383035
   PubMed Web of Science ®Google Scholar
• BenkertOMüller-SiechenederFWetzelHDopamine agonists in schizophrenia: a reviewEur Neuropsychopharmacol.19955suppl43538775758
   PubMed Web of Science ®Google Scholar
• KasperSBarnasCHeidenAPramipexole as adjunct to haloperidol in schizophrenia: safety and efficacyEur Neuropsychopharmacol1997765709088887
   PubMed Web of Science ®Google Scholar
• GentileSExtrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorderJ Clin Psychopharmacol200727354517224710
   PubMed Web of Science ®Google Scholar
• BurrisKDMolskiTFRyanEAripiprazole is a high affinity partial agonist at human dopamine D2 receptorsInt J Neuropsychopharmacol20003suppl 1S129
   PubMed Web of Science ®Google Scholar
• ShapiroDARenockSArringtonSAripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacologyNeuropsychopharmacology2003281400141112784105
   PubMed Web of Science ®Google Scholar
• StarkADJordanSAllersKAInteraction of the novel antipsychotic aripiprazole with 5-HT(1A) and 5-HT(2A) receptors: functional receptor-binding and in vivo electrophysiological studyPsychopharmacology (Berl.)200719037338217242925
   PubMed Web of Science ®Google Scholar
• KeckPEMcElroySLAripiprazole: a partial dopamine D2 receptor agonist antipsychoticExpert Opin Invest Drugs200312655662
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research [homepage on the Internat]. Application number 21–436.Clinical pharmacology and biopharmaceutics review(s). Available from http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm Accessed: September 11, 2008
   Google Scholar
• Active ingredient: Aripiprazole - Basic Profile/Key Facts [homepage on the Internet]. Available from URL: http://www.druglib.com/active-ingredient/aripiprazole/ Accessed September 11, 2008.
   Google Scholar
• LawlerCPPrioleauCLewisMMInteractions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypesNeuropsychopharmacology19992061262710327430
   PubMed Web of Science ®Google Scholar
• CalmanKCQuality of life in cancer patients: a hypothesisJ Med Ethics1984101241276334159
   PubMed Web of Science ®Google Scholar
• WareJEConceptualizing disease impact and treatment outcomeCancer198453231623236367942
   PubMed Web of Science ®Google Scholar
• Wood-DauphineeSWilliamsJLReintegration in normal living as a proxy to quality of lifeJ Chronic Dis1987404915023597654
   PubMedGoogle Scholar
• HornquistJ-OQuality of life: concept and assessmentScand J Soc Med19891869792320980
   PubMedGoogle Scholar
• FerransCEQuality of life: conceptual issuesSem Oncol Nurs19906248254
   PubMedGoogle Scholar
• KalfossMHRingelKSGundersenV1998the World Health Organization’s Quality of Life Assessments (WHOQOL – 100 and WHOQOL – brief) knowledge development: clinicians and researchers in partnershipProceedings from the 9th Biennial Conference and Workshop of European Nurse ResearchersJuly 5–8, 1998Helsinki376387
   Google Scholar